NCT07699172

Brief Summary

Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor surgery. Participants will undergo standardized neuropsychological assessments together with preoperative, intraoperative, and postoperative electrophysiological recordings. The study will investigate whether EEG-based neural decoding can improve objective cognitive function assessment and support individualized functional preservation during brain tumor surgery.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
24mo left

Started Aug 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 3, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 13, 2026

Completed
19 days until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2028

Last Updated

July 13, 2026

Status Verified

July 1, 2026

Enrollment Period

2 years

First QC Date

July 3, 2026

Last Update Submit

July 9, 2026

Conditions

GliomaBrain NeoplasmBrain Tumor Adult

Keywords

ElectroencephalographyEEGNeural Signal DecodingCognitive FunctionCognitive PreservationBrain Tumor Surgery

Outcome Measures

Primary Outcomes (2)

  • Mini-Mental State Examination (MMSE) Total Score

    Cognitive function assessed using the Mini-Mental State Examination (MMSE). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.

    Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months

  • Montreal Cognitive Assessment (MoCA) Total Score

    Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.

    Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months

Study Arms (1)

EEG-Guided Cognitive Function Preservation

EXPERIMENTAL

Participants undergoing brain tumor surgery will receive the EEG-based neural signal decoding strategy in addition to standard surgical management for individualized cognitive function preservation. Cognitive outcomes will be evaluated using standardized neuropsychological assessments.

Procedure: EEG-Based Neural Signal Decoding Strategy

Interventions

EEG-Based Neural Signal Decoding StrategyPROCEDURE

EEG-based neural signal decoding will be performed during the perioperative period to identify cognitive functional networks and assist individualized cognitive function preservation during brain tumor surgery.

EEG-Guided Cognitive Function Preservation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years to 75 years.
  • Patients diagnosed with brain glioma and scheduled for surgical treatment.
  • Conscious and able to understand study procedures.
  • Able to complete neuropsychological assessments.
  • Willing to participate and provide written informed consent.

You may not qualify if:

  • Severe dysfunction of major organs (heart, lung, liver, or kidney).
  • Severe psychiatric disorders or cognitive impairment.
  • Severe language impairment preventing completion of study procedures.
  • Any other condition judged by the investigator to make participation inappropriate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Huanhu Hospital

Tianjin, Tianjin Municipality, 300350, China

Location

MeSH Terms

Conditions

GliomaBrain Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Central Study Contacts

Bo Wang

CONTACT

022-59065262dr.bo.wang@tmu.edu.cn

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Chief Physician

Study Record Dates

First Submitted

July 3, 2026

First Posted

July 13, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

July 31, 2028

Study Completion (Estimated)

July 31, 2028

Last Updated

July 13, 2026

Record last verified: 2026-07

Locations

CN(1)